期刊文献+

达英-35对多囊卵巢综合征患者糖脂代谢的影响 被引量:30

Effects of Diane-35 on the glucose and lipid metabolism in patients with polycystic ovary syndrome
在线阅读 下载PDF
导出
摘要 目的观察达英-35治疗多囊卵巢综合征(polycystic ovary syndrome,PCOS)的疗效,探讨其对PCOS患者激素及糖脂代谢的影响。方法将确诊为PCOS的100名患者按照国际糖尿病联盟对代谢综合征的诊断分为代谢综合征(metabolic syndrome,MS)组和非代谢综合征组(non-MS)。观察并比较两组采用达英-35治疗3个月前后的激素、糖脂代谢指标的变化。结果治疗后MS组体质量指数显著降低,非MS组无明显改变;两组血清睾酮和黄体生成素(luteinizing hormone,LH)/测量卵泡刺激素(follicle stimulating hormone,FSH)明显下降(P<0.05);MS组总胆固醇降低,非MS组显著升高,两组间变化幅度比较,差异近似有统计学意义(P=0.054);两组三酰甘油浓度均有显著升高,MS组升高幅度较大,组间差异有统计学意义(P<0.05);MS组高密度脂蛋白胆固醇(high density lipoprotein-cholesterol,HDL-C)在治疗后略有上升,而非MS组显著升高,组间比较差异无统计学意义(P<0.05);MS组LDL-C均有轻度下降,非MS组则略有上升,组间比较差异有统计学意义(P<0.05)。MS组空腹血糖显著下降,非MS组显著上升,组间比较差异有统计学意义(P<0.05)。MS组空腹胰岛素轻度下降,非MS组轻度上升,组间比较差异无统计学意义(P>0.05)。结论达英-35能够调整月经周期,改善高雄激素状态,并不恶化PCOS的糖脂代谢。在治疗过程中,除药物治疗外,还应注意配合饮食控制和运动,以期达到更好的疗效。 Objective To observe the effects of Diane-35 on polycystic ovary syndrome( PCOS),and to investigate its influence on hormone,glucose and lipid metabolism in PCOS patients. Methods Totally 100 patients diagnosed as PCOS were divided into two groups,metabolic syndrome( MS) group( n = 64) and non-MS group( n = 36),according to the MS criteria formulated by International Diabetes Federation( IDF). Hormone level and parameters of glucose and lipid metabolism were detected and compared between the two groups before and after treatment by Diane-35 for 3 months. Results The body mass index decreased significantly after treatment in MS group,while no obvious change in non-MS group. The serum testosterone and LH / FSH decreased in both groups( P〈0. 05). The total cholesterol in MS group slightly decreased,but increased significantly in non-MS group. The triglyceride in both groups increased significantly,especially in MS group,and the difference between the groups was statistically significant. HDL-C increased in both group,but only increased significantly in non-MS group( P〈0. 05). LDL-C decreased in MS group and increased in non-MS group without statistical difference,but the difference of between the groups was statistically significant. Fasting glucose decreased in MS group and increased in non-MS group significantly,and the difference between the groups was statistically significant. Fasting insulin decreased in MS group and increased in non-MS group without significant difference,and the difference between the groups was not significant.Conclusion Diane-35 can modify the menstrual cycle,and improve the hyperandrogenism such as hirsutism and acne,and do not deteriorate the glucose and lipid metabolism. PCOS treatment should combine diane-35 with diet and exercise,helping PCOS patients achieving the best effect.
出处 《首都医科大学学报》 CAS 北大核心 2016年第4期424-430,共7页 Journal of Capital Medical University
基金 北京市自然科学基金(Y161011) 北京市卫生系统高层次卫生技术人才(2014-2-016) 国家外国专家局2016年度北京市引进国外技术 管理人才项目(高外端)(20161100031) 首都医科大学附属北京妇产医院 北京妇幼保健院学科带头人项目(2013-1)~~
关键词 多囊卵巢综合征 代谢综合征 达英-35 糖脂代谢 polycystic ovary syndrome metabolic syndrome Diane-35 glucose and lipid metabolism
作者简介 Corresponding author.E-mail:ruanxiangyan@163.com
  • 相关文献

参考文献22

  • 1Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group.Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome(PCOS)[J].Hum Reprod,2004,19(1):41-47.
  • 2Alberti K G,Zimmet P,Shaw J.et al.The metabolic syndrome—a new worldwide definition[J].Lancet,2005,366(9491):1059-1062.
  • 3Alberti KGMM,Eckel R H,Grundy S M,et al.Harmonizing the metabolic syndrome:a joint interim statement of the international diabetes federation task force on epidemiology and prevention;national heart,lung,and blood institute;american heart association;world heart federation;international atherosclerosis society;and international association for the study of obesity[J].Circulation,2009,120(16):1640-1645.
  • 4Bil E,Dilbaz B,Cirik D A.Metabolic syndrome and metabolic risk profile according to polycystic ovary syndrome phenotype[J].J Obstet Gynaecol Res,2016,42(7):837-843.
  • 5Kelly C C,Lyall H,Petrie JR,e t al.Low grade chronic inflammation in women with polycystic ovarian syndrome[J].J Clin Endocrinol Metab,2001,86(6):2453-2435.
  • 6Gallo M F,Lopez L M,Grimes D A,et al.Combination contraceptives:effects on weight[J].Cochrane Database Syst Rev,2014,29(1):CD003987.
  • 7Orbetsova M,Kamenov Z,Kolarov G,et al.Effect of 6-month treatment with oral antiandrogen alone and in combination with insulin sensitizers on body composition,hormonal and metabolic parameters in women with polycystic ovary syndrome(PCOS)in order to determine therapeutic strategy[J].Akush Gimekol:sotilia,2006,45(7):16-28.
  • 8Wu H,Ruan X,Jin J,et al.Metabolic profile of Diane-35versus Diane-35 plus metformin in Chinese PCOS women under standardized life-style changes[J].Gynecol Endocrinol,2015,31(7):548-551.
  • 9Trikudanathan S.Polycystic ovarian syndrome[J].Med Clin North Am,2015,99(1):221-235.
  • 10Hsu M I,Liou T H,Liang S J,et al.Inappropriate gonadotropin secretion in polycystic ovary syndrome[J].Fertil Steril,2009,91(4):1168-1174.

二级参考文献69

  • 1孙红卫,徐应军,庞淑兰,李美芝.胰岛素抵抗和非胰岛素抵抗多囊卵巢综合征患者的临床特征[J].中国综合临床,2005,21(9):845-847. 被引量:4
  • 2梅志雄,覃炜.二甲双胍联合复方醋酸环丙孕酮治疗多囊卵巢综合征40例临床分析[J].南方医科大学学报,2006,26(5):657-658. 被引量:8
  • 3于传鑫,李诵铉.实用妇科内分泌学[M].2版.上海:复旦大学出版社,2006:442.
  • 4Berger M J, Taymor ML, Patton WE. Gonadotropin levels and secretory patterns in patients with typical and atypical polycystic ovarian disease. Fertil Steril, 1975,26:619-626.
  • 5Cho LW, Jayagopal V, Kilpatrick ES, et al. The LH/FSH ratio has little use in diagnosing polycystic ovarian syndrome. Ann Clin Biochem. 2006,43:217-219.
  • 6Hendriks ML, Brouwer J, Hompes PG,et al. LH as a diagnostic criterion for polycystic ovary syndrome in patients with WHO Ⅱ oligo/amenorrhoea. Reprod Biomed Online, 2008,16:765-771.
  • 7Stein IL, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol,1935 ,29 :181-191.
  • 8Geisth~vel F. A comment on the European Society of Human Reproduction and Embryology/American Society for Reproductive Medicine consensus of the polycystic ovarian syndrome. Reprod Biomed Online ,2003,7:602-605.
  • 9生殖内分泌委員会.多囊胞性卵巢症候群の新诊断基準(案)[J].日本産科婦人科雜誌,2007,59:868-886.
  • 10Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab, 1961,21:1440-1447.

共引文献150

同被引文献281

引证文献30

二级引证文献216

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部